Cellenkos, Inc.
Clinical trials sponsored by Cellenkos, Inc., explained in plain language.
-
Cord blood cells aim to break transfusion dependence in aplastic anemia
Disease control Not yet recruitingThis study tests a new treatment called CK0801 for adults with aplastic anemia who still need blood transfusions after standard treatments. CK0801 uses immune cells from donated cord blood to help the body make its own blood cells again. The goal is to see if it is safe and can r…
Phase: PHASE2 • Sponsor: Cellenkos, Inc. • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
New immune cell therapy aims to tame deadly transplant complication
Disease control Not yet recruitingThis early-phase trial tests CK0802, a therapy made from special immune cells called Tregs, for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant where donor cells atta…
Phase: PHASE1, PHASE2 • Sponsor: Cellenkos, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC